Search results
Showing 16 to 22 of 22 results for gefitinib
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]
In development Reference number: GID-TA10899 Expected publication date: TBC
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)
Evidence-based recommendations on ramucirumab (Cyramza) for locally advanced or metastatic non-small-cell lung cancer in adults who have had platinum-based chemotherapy.
Discontinued Reference number: GID-TAG422
Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer after chemotherapy in adults.
Discontinued Reference number: GID-TA11289
This guidance has been updated and replaced by NICE technology appraisal guidance 374.
NICE has developed a medtech innovation briefing (MIB) on plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer .